Medical research

Research uncovers additional treatment option in prostate cancer

The standard treatment for advanced metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). And even if this is efficient in the short term, 1/3 of PCa will become resistant to ADT and develop castration-resistant ...

Oncology & Cancer

Immunotherapy offers hope for prostate cancer treatment

An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase ...

Oncology & Cancer

Darolutamide boosts survival in nonmetastatic prostate cancer

(HealthDay)—For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue ...

Medications

Relugolix superior to leuprolide in advanced prostate cancer

(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...

Oncology & Cancer

Driver found for more deadly prostate cancer

A transcription factor that aids neuron function also appears to enable a cell conversion in the prostate gland that can make an already recurrent cancer even more deadly, scientists say.

page 1 from 2